BioWorld Asia

Sep. 19, 2007

NeuroSearch Shares Boosted By Tesofensine Obesity Data

Shares in NeuroSearch A/S gained almost 22 percent Monday on news that its candidate obesity drug tesofensine attained an average weight reduction of about 10 ten percent in a Phase IIb clinical trial. (BioWorld International) Read More

Ganymed Adds To Series C; Closes 37.2M Financing Round

No Abstract Read More

Gene Expression Levels Vary At Higher Levels Than Thought

Oxford BioMedica Using Sanofi Deal As Catalyst For Growth

European Industry Seeks Wider Links In Orphan Drug Programs

Other News To Note

Renovo Reports Positive Data From Phase IIb Trial Of Juvista

Mutabilis, Oroxcell Collaborate On Preclinical Antibiotic Agent

EU Commissioner Defends Rule Banning GM-Free Zones

Today's news in brief

BioWorld

Precision psychiatry beyond, or before, biomarkers

BioWorld

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...

Keros reports beneficial effects of RKER-065 in ALS model

BioWorld Science

Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.

News in brief

BioWorld Asia

BioWorld Asia briefs for March 17, 2026

First-in-class POLG activator restores mtDNA across mutations

BioWorld Science

Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...